Skip to main
NUVB

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio is a promising biopharmaceutical company with a strong pipeline and a diversified revenue stream through out-licensing agreements. They have a promising candidate, taletrectinib, for the treatment of ROS1+ NSCLC, and other potential candidates in clinical development. Their financials show positive growth potential, and potential risks include negative clinical data, competition in the market, and physician adoption. Overall, the company's strong potential and strategic initiatives make them a compelling investment opportunity.

Bears say

Nuvation Bio is a relatively new biopharmaceutical company with a limited track record and a small pipeline focused primarily on one product for a specific type of lung cancer. While their partnership with Japan does provide some revenue opportunities, the success of their product Ibtrozi and ongoing development for safusidenib in mIDH1 glioma is the main driver of their valuation, which carries significant commercialization and regulatory risks.

Nuvation Bio (NUVB) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Buy based on their latest research and market trends.

According to 8 analysts, Nuvation Bio (NUVB) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.